Over the past three years, few therapeutic categories have reshaped the healthcare landscape as dramatically as the emergence of GLP-1 receptor agonists. Medicines such as semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) have moved from being niche diabetes therapies to becoming central players in the global obesity conversation.
Demand for these medicines has surged. Pharmacies across Australia have experienced unprecedented interest from patients seeking weight-loss solutions, driven by media coverage, social media narratives, and the promise of meaningful reductions in body weight.
Clinical trials have confirmed that these medicines can produce significant weight loss, often in the range of 10–15% or more when combined with lifestyle interventions. In addition, the recently published SELECT trial demonstrated that semaglutide reduced major cardiovascular events in people with obesity and established cardiovascular disease, even in the absence of diabetes (Lincoff et al., New England Journal of Medicine, 2023).
These findings represent a genuine therapeutic advance.
However, as the rapid adoption of GLP-1 medications continues, an equally important discussion is emerging within clinical circles: what are the long-term metabolic consequences of relying primarily on pharmacological appetite suppression for weight management?
For community pharmacists, who often serve as the most accessible healthcare professionals in the system, this question deserves careful consideration.
Weight Loss Versus Metabolic Health
Obesity management has always involved more than simply reducing body weight. Long-term health outcomes are closely tied to factors such as lean muscle mass, metabolic flexibility, nutritional adequacy, and behavioural sustainability.
GLP-1 medications work primarily by slowing gastric emptying and influencing appetite regulation within the central nervous system. By reducing hunger and caloric intake, they allow many patients to lose weight more effectively than through traditional dieting approaches alone.
But weight loss itself does not automatically equate to improved body composition or metabolic resilience.
An important emerging area of discussion relates to the proportion of lean body mass lost during rapid weight reduction.
Several analyses have suggested that between 25% and 39% of weight lost during GLP-1 therapy may represent lean mass rather than fat mass (Chaudhry et al., NIH review of GLP-1 body composition data). While this does not imply harmful muscle wasting in every patient, it highlights an important physiological reality: rapid weight loss often involves the loss of both fat and muscle unless specific countermeasures are implemented.
For patients—particularly older adults—this matters greatly.
Skeletal muscle is a central driver of metabolic health. It plays a key role in glucose regulation, energy metabolism, functional mobility, and long-term weight maintenance. Loss of muscle mass can contribute to reduced strength, lower metabolic rate, and increased vulnerability to weight regain.
In other words, protecting muscle may be just as important as reducing fat.
The Reality of Weight Regain
Another critical issue for healthcare providers is the sustainability of weight loss once GLP-1 therapy is discontinued.
In the extension phase of the STEP-1 trial, participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year, along with partial reversal of cardiometabolic improvements (Wilding et al., Diabetes, Obesity and Metabolism, 2022).
This finding does not invalidate the usefulness of the medication, but it does suggest that GLP-1 therapy often functions as a long-term management strategy rather than a short-term cure.
For pharmacists, this raises practical and ethical considerations.
If patients are using medication to suppress appetite without simultaneously developing sustainable nutritional habits and lifestyle practices, there is a risk that the underlying drivers of obesity remain unaddressed.
When the medication is stopped—whether due to cost, supply issues, or side effects—the patient may simply return to previous behavioural patterns.
Safety and Monitoring Considerations
GLP-1 receptor agonists are generally considered safe when used appropriately under medical supervision. Nevertheless, regulatory authorities such as the U.S. Food and Drug Administration and other agencies highlight a number of potential adverse effects.
These include gastrointestinal disturbances, delayed gastric emptying, gallbladder disease, pancreatitis, and in certain cases kidney complications related to dehydration.
For pharmacists, patient counselling around these potential effects remains essential.
However, an equally important dimension is the nutritional context in which these medicines are used.
Because GLP-1 medications suppress appetite, some patients may significantly reduce food intake without carefully maintaining adequate protein consumption or overall nutrient density. When this occurs, the risk of lean mass loss and fatigue may increase.
This is particularly relevant for patients who are not receiving structured dietary guidance.
The Pharmacist’s Expanding Role
Community pharmacy has increasingly moved toward service-based healthcare, including medication reviews, chronic disease management, and preventative care.
The rise of GLP-1 therapy presents an opportunity for pharmacists to expand their role even further—not simply as dispensers of medication, but as advocates for comprehensive metabolic health strategies.
Rather than viewing obesity treatment solely through a pharmaceutical lens, pharmacists are uniquely positioned to encourage patients to adopt broader lifestyle approaches that support the effectiveness of medication while protecting long-term health.
This may include emphasising:
- adequate dietary protein to support muscle preservation
- resistance training or strength-based activity
- whole-food nutrition patterns that support satiety and metabolic balance
- behavioural coaching and ongoing lifestyle support
In many cases, medication and lifestyle intervention may work best together rather than in isolation.
The Case for Whole-Food Lifestyle Programs
A growing body of research supports the role of structured lifestyle programs in long-term weight management and metabolic health.
Whole-food dietary approaches that emphasise minimally processed foods, balanced macronutrients, adequate protein intake, and sustainable eating patterns can help address many of the underlying drivers of obesity.
Such approaches can also complement pharmacological therapies by helping patients maintain muscle mass, stabilise energy levels, and develop long-term dietary habits that persist beyond medication use.
For pharmacists working with patients on GLP-1 therapy, introducing or referring patients to credible nutrition and lifestyle programs may significantly enhance outcomes.
Rather than seeing lifestyle intervention as an alternative to medication, it may be more productive to view it as the foundation upon which medical therapies operate most effectively.
A Balanced Future for Weight Management.jpg?width=644&height=429&name=plate-with-keto-diet-food-fried-egg-bacon-avocado-arugula-strawberries-keto-breakfast%20(1).jpg)
The emergence of GLP-1 therapies represents one of the most significant pharmaceutical developments in obesity management in decades.
Yet the broader lesson may be that no single intervention is sufficient on its own.
Medications can support appetite regulation and initial weight loss. However, sustainable metabolic health almost certainly requires the integration of nutrition, physical activity, behavioural change, and long-term support.
For community pharmacists, the current moment represents both a challenge and an opportunity.
The challenge lies in navigating a rapidly evolving therapeutic landscape where patient demand for pharmaceutical solutions is high.
The opportunity lies in helping patients understand that weight loss is not merely about reducing numbers on a scale, but about building lasting metabolic resilience.
By encouraging patients to combine appropriate medical therapy with structured lifestyle strategies—including whole-food nutrition and muscle-preserving activity—pharmacists can play a critical role in improving long-term outcomes.
In the GLP-1 era, perhaps the most valuable question pharmacy professionals can ask is not simply “How can we help patients lose weight?”
But rather:
“How can we help patients build lasting health?”
References
Lincoff AM et al.
Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes.
New England Journal of Medicine. 2023.
Wilding JPH et al.
Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide.
Diabetes, Obesity and Metabolism. 2022.
Chaudhry Z et al.
Body Composition Changes During GLP-1 Receptor Agonist Therapy.
National Institutes of Health / PubMed.
National Institute for Health and Care Excellence (NICE).
Semaglutide for managing overweight and obesity. 2023.
U.S. Food and Drug Administration.
Wegovy (semaglutide) Prescribing Information.
Meet Malcolm Today!
.jpg?width=329&height=439&name=Malcolm%20New%20Headshot_%20(1).jpg)
Founder and General Manager of UltraLite Program
Join UltraLite Today!
For 26 years, UltraLite’s healthy ketogenic program has changed lives. Join the success stories—or step up and help others succeed as an UltraLite practitioner.
.jpg?width=424&height=282&name=Untitled%20design%20(1).jpg)
